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ABSTRACT 
Ongoing efforts towards the development of CO-based therapeutics have resulted in the 
generation of novel CO prodrugs that release CO via different triggers or stimuli. Here in, we 
designed and synthesized organic CO prodrugs with a tethered cytotoxic agent to achieve a co-
delivery of CO and the cytotoxic drug under physiological conditions by leveraging on the inverse 
electron-demand Diels-Alder reaction as the trigger. We also attempted to characterize, kinetically 
and spectroscopically, some of the organic CO prodrugs synthesized by our lab. The results 
showed that these prodrugs released CO under near physiological condition with controllable and 
tunable release rate. 
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1 STRATEGIES EMPLOYED IN PRODRUG ACTIVATION 
1.1 Introduction  
Despite the achievements made thus far by chemotherapy in the fight against cancer, its 
reliability has been limited by issues such as poor selectivity, toxicity, and inefficiency in the 
treatment of slow growing solid tumors. The activity of chemotherapy drugs is mainly based on 
anti-proliferating effect, thus making their use unsuitable for prolonged treatment of cancer, as this 
results to lethal damage to proliferating non-malignant cells.1  
Targeted prodrug strategies have been employed as a panacea to circumvent the problems 
associated with cancer chemotherapy. In this approach, the cytotoxic drug is conjugated to a carrier 
ligand which has high affinity for tumor-associated markers such as antigens or receptors. The 
drug-ligand conjugate is transported by the carrier to the target cell where it is released either 
extracellularly or intracellularly to initiate its cytotoxic effect. 
Activation of prodrugs can be achieved via cleavage of chemical linkers between the drug 
and the carrier ligand (promoiety). This usually relies on certain triggerable conditions in the tumor 
such as the presence of an overexpressed enzyme or changes in pH.2 However, activation triggered 
by enzymes has its own drawback as the tumor cell may be deficient in the target overexpressed 
enzyme or the target enzyme may be expressed inside the cell which necessitates the entering of 
the prodrug. Moreover, the subtlety of the changes in the tumor environment hampers selective 
activation of the prodrug, leading to low tumor-to-background ratio,1 and many of the linkers have 
been shown to be susceptible to off-target hydrolysis.2  
Another approach that has been used to address the lack of selectivity of chemotherapy 
drugs is the use of antibody-drug conjugates (ADCs). This approach relies on the high affinity of 
the antibody to effectively transport the prodrug to the tumor cell.1 Although ADCs have been 
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successfully utilized over the years to overcome the challenges of chemotherapy, factors such as 
immunogenic potential, cell selectivity, and cell permeability are hurdles to overcome in the design 
of ADCs.2 Also, the biodistribution of antibody-drug conjugate prodrugs is limited by 
heterogeneity of the tumor with respect to vascularization and interstitial pressure, and dictates the 
concentration of the drug at the tumor site.3 These issues can be bypassed with the use of 
bioorthogonal-triggered release in pre-targeted strategies.4-9   
Bioorthogonal chemical reaction has received an avalanche of interest and applications in 
in vivo studies, including detection of DNA and RNA synthesis, visualization of site-specific 
tagging of proteins, detection of post-translational modifications in proteins, and monitoring of 
cellular processes.10, 11 Some examples of prodrug activation strategies that have employed 
bioorthogonal-triggered release in in vivo application include: activation of a doxorubicin prodrug 
in which the Staudinger reaction was used as the prodrug activator.12 Here the active doxorubicin 
was released in a cell culture environment after the reaction between an azido-functionalized 
prodrug (1) and a triphenylphosphine (2) (Scheme 1). Although this method was efficient in terms 
of its selective cleavage of the prodrug, it is, however, hindered by its slow reactivity, and the 
phosphine reagents are prone to oxidation.4 Another example is the trans-cyclooctene 
(TCO)/tetrazine ligation for prodrug activation,4 in which the active drug was released via an 
intermediate rearrangement. In spite of its fast kinetics, a number of issues related to off-target 
hydrolysis of the ADC due to low ratio of drug to tumor, and reduced reactivity of TCO-conjugate 
in the presence of bulky substituents, have been identified to impede its in vivo application.9 A 
more recent example of bioorthogonal prodrug activation strategy is the one driven by strain-
promoted 1, 3-dipolar cycloaddition where a trans-cyclooctene-antibody conjugate (5) was “click” 
with a prodrug (6) that encompasses the cytotoxic drug conjugated via  the carbamate self-
3 
immolative linker to the p-azidobenzyl group. Controlled release of the active drug was achieved 
via unstable triazole intermediate (7) which undergo a rearrangement to an acid-labile imine (9). 
The in situ generated imine, in the tumor environment, subsequently, undergo acid-catalyzed 
hydrolysis, resulting to 1, 6-elimination of the active drug (12) (Scheme 2).9 Again, dependence 
of the drug release on the tumor environment constitute a limiting factor. 
 
Scheme 1: Activation of a doxorubicin prodrug using the Staudinger reaction between a 
triphenylphosphine (1) and an azido-funtionalized prodrug (2). 
 
Scheme 2: Prodrug activation using 1, 3-dipolar cycloaddition as the trigger. 
2 CO AS A GASOTRANSMITTER: PHYSIOLOGICAL EFFECTS AND 
THERAPEUTIC POTENTIAL 
 Carbon monoxide (CO) has had a long-standing reputation as a toxic, poisonous gas. This 
is not unconnected to its strong affinity for hemoglobin, reducing the oxygen-carrying capacity of 
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the protein, and as an air pollutant. Hence, for decades, scientists have paid little attention to carbon 
monoxide research. However, recent studies and research have demonstrated a lot of biological 
and therapeutic relevance of the gas.13-19  
Carbon monoxide is one of a family of gasotransmitters with importance on par with that 
of NO and H2S in mammalian systems.
20, 21 Endogenous CO is generated by heme metabolism, 
which is catalyzed by the heme oxygenase HO. The products of this catabolic pathway are ferrous 
iron, carbon monoxide, and billiverdin. There are two isoforms of heme oxygenase (HO-1 and 
HO-2) that mediate the degradation of heme, while the HO-1 isoform is implicated in oxidative 
stress or pathophysiological conditions, and thus, referred to as the inducible form, the HO-2 
isoform is expressed constitutively in various tissues, including neurons, liver, kidney, and the 
vascular endothelium.13, 22 Experimental investigation into the physiological relevance of CO 
reveals the roles of CO in mediating physiological processes such as vasodilation, 
neurotransmission, inhibition of platelet aggregation and anti-proliferating effects on vascular 
smooth muscle cells. For instance, CO regulates the activity of soluble guanylate cyclase (sGC), 
an important regulator of neurotransmission, by inducing a conformational change of the protein.19 
Increased generation of reactive oxygen species (ROS) has been associated with CO regulation of 
the cellular levels of superoxide.23 CO regulates cellular behavior by the enhancement of 
mitochondria biogenesis, and increase in the cellular level of ATP.19 
The anti-inflammatory effects of CO can be seen in its ability to efficiently block the 
expression of the proinflammatory proteins interleukin-1β, lipopolysaccharide (LPS)-induced 
tumor necrosis factor (TNF)-α and macrophage inflammatory protein-1β. CO prevents cell and 
tissue injury, and plays important role in cell proliferation.14 
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In terms of its therapeutic potential, CO has important roles, and has imparted the treatment 
of cancer in so many ways. For instance, enzymatically dormant HO-1, localized in the nucleus of 
cancer cells, has been associated with tumor aggressiveness, thus, revealing its potential as a 
modulator of cancer progression. Indeed, histopathological studies revealed that long GT repeat in 
the promoter region of HO-1 and lower HO-1 expression are associated with chronic state of 
cancer. Also, renal cancer, gastric cancer, and melanoma have all been associated with 
overexpression of HO-1. However, CO can stimulate the expression of HO-1, in this way, acting 
as a regulator of tumorigenesis.24 In addition, HO-1, through its antioxidant mechanism, has been 
shown to exhibit anti-proliferative and proapoptotic effects. Furthermore, CO has been shown to 
induce anti-Warburg effect by switching the metabolic state of cancer cells to fuel their 
bioenergetics and suppress biogenesis.24 This ultimately results to metabolic exhaustion. Cancer 
cells make use of the Warburg effect, a phenomenon that favors the lactic acid dehydrogenase 
(LDH) pathway owing to high glucose uptake and elevated levels of glycolysis under hypoxia 
condition, to promote their growth and metastasize to other tissues and organs, and to develop 
resistance against chemotherapy drugs such as taxols, doxorubicin, and cisplatin. Their growth is 
also supported by suppressed mitochondrial activities and biogenesis. Defects in reactive oxygen 
species (ROS) metabolism has also been associated with cancer metastasis.24 CO reverses these 
processes via enhancement of mitochondria activities of cancer cells, leading to metabolic 
exhaustion, cell arrest, and apoptosis. CO exhibited chemosparing property by providing 
protection for heart tissues against doxorubicin-induced cardiotoxicity.25 It is also shown to 
sensitize cancer cells to chemotherapeutics, thus improving their therapeutic efficacy, while 
shielding the surrounding normal proliferating cells.24-26 Given the therapeutic profile of CO in 
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cancer therapy, in addition to its chemosparing property, we intend to take advantage of the 
synergistic effect of combining CO with chemotherapy in cancer therapy. 
One agitation about the possibility of using CO as a therapeutic has been centered around 
its safety window. CO has been shown to have a safety margin of more than ten-fold, a safety 
margin wider than that of nutrients such as glucose, metal ions, and most clinically approved 
drugs.26 Studies involving healthy humans showed that carboxyhemoglobin (COHb) levels in 
blood at 12% due to inhaled CO was well tolerated with no ramifications, and with CO having 
clear distribution and elimination profiles.19 All the above information have revealed a lot on the 
therapeutic potential of CO. However, there is a great amount of work that needs to be done in 
terms of developing an efficient system that is capable of delivery CO, in a well-controlled manner, 
at specific target site. This means that the system must encompass a CO-prodrug with tunable 
release rate. 
So far, there are three identifiable forms of CO delivery. They include gaseous delivery at 
low concentration, use of physiological solutions saturated with CO gas, and molecular entities 
that are capable of releasing CO in a controlled manner, known as carbon monoxide releasing 
molecules (CORMs).16 While the applicability of the second mode of delivery is limited, there are 
many issues associated with gaseous delivery. Some of which include, but not limited to, lack of 
targetability, reliability, control, effective concentration and limitation to hospital settings.16, 26 The 
carbon monoxide releasing molecules (CORMs) are divided into two groups: the metal-based 
CORMs which encompass the transition metal carbonyls based around manganese, ruthenium or 
molybdenum, releasing CO upon exposure to light, water or enzyme; and metal-free CORMs.16, 27 
The metal-based CORMs have been successfully employed in both in vitro and in vivo studies 
where they provide cardioprotection, safely deliver CO for the treatment of various diseases, and 
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exhibited anti-inflammatory, vasodilatory and anti-ischemic effects.16  The first generation of 
metal-based CORMs include the dimanganese dicarbonyl (CORM-1), 
tricarbonyldichlororuthenium dimer (CORM-2), tricarbonylchloro (glycinato) rutheniunm 
(CORM-3), and the boron-containing carboxylic acid, CORM-A1.13 While CORM-1 and CORM-
2 are lipid-soluble, releasing CO in DMSO on interaction with deoxymyoglobin or 
deoxyhemoglobin with half-lives of < 1 min and 1 min respectively, CORM-3 and CORM-A1 
which are water-soluble, release CO under physiological conditions with half-lives 1 min and 21 
min respectively.26 A more recent CORM which is activated by light is the photosensitive CORM, 
[Mn(pqa)(CO)3](ClO4); pqa = 2-pyridylmethyl)(2-quinolymethyl)amine). These metal-based 
CORMs have helped shaped and broaden our understanding of the biological and physiological 
functions of carbon monoxide. However, the continuous use of these metal-based CO therapeutics 
has been relegated by the potential toxicity pose by transition metals and perceived issues that 
seem to pose life-threatening situations.26 The toxicity issue is based on the fact that these metals, 
which are present in trace amount, are tightly regulated in the body, the source of challenge in the 
development of these CORMs. Also, the byproduct of some of these metal-based CORMs has 
unpredictable effect on the pH of the body. With these issues at stake, the need therefore arises for 
the development of metal-free CORMs with desirable pharmaceutical properties. This class of 
novel CORMs must have the following features: no toxicity for both the CORM and its inactive 
products, controlled release of CO with tunable release rate under physiological conditions, 
triggered release, targeted or localized delivery, and easy to formulate using existing approaches.26, 
27 Organic CORMs represent a novel class of carbon monoxide releasing molecules with potential 
to attain these desirable pharmaceutical properties. 
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Our group has pioneered this direction with the design of an organic CO-prodrug with 
tunable rate, that releases CO under physiological conditions, via a click-and-release approach 
based on the inverse electron-demand Diels Alder reaction (DAinv).
27 The reaction is between the 
strained alkyne, bicyclo[6.1.0]nonyne (BCN, 13a), characterized with high HOMO energy and the 
diene, tetraphenylcyclopentadienone (TPCPD, 14a) (Fig. 1). TPCPD is known to undergo the 
DAinv reaction, releasing CO under very rigorous conditions such as high temperature; thus, 
TPCPD is a form of “caged” CO. The ability of this carbonylketone to furnish CO is due to energy 
strain conferred on the transition state of the DAinv reaction.
28 However, the hash  
 
Figure 1. The click reaction between BCNs and TPCPDs 
condition that characterized the reaction makes it unsuitable for therapeutic applications. It is 
therefore reasoned that if a high-energy HOMO alkyne such as BCN is “click” with TPCPD, it 
will allow the release of CO under mild conditions, and by extension, physiological conditions. Of 
course, this is possible as the rate of the DAinv reaction depends on the HOMO-LUMO energy gap. 
The use of a high-energy HOMO alkyne will essentially narrow the energy gap, consequently 
leading to a higher reaction rate. Indeed, when the BCN (13a) and TPCPD (14a) reaction was 
examined, the reaction proceeded successfully in methanol at ambient temperature with a second-
order rate constant of 0.61 M-1 S-1.27 However, due to the toxicity of the 13a and 14a, compounds 
13b and 14b with the sugar moieties were employed to attenuate the potential toxicity of 13a and 
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14a. Cell viability studies showed no toxicity with 13b and 14b. Evaluation of their anti-
inflammatory effects in RAW 264.5 cells shows 13b and 14b effectively inhibit LPS-induced 
TNF-α.27 These data demonstrated the efficiency of the organic CO-prodrug in delivery CO in 
biological systems, and also its therapeutic potential for in vivo biological applications. 
Here, we designed and synthesized organic CO-prodrug with tethering cytotoxic agent, and 
then tested the release rate and further examined the synergistic effects of our prodrug system. 
2.1 Results and Discussion 
Motivated by the outcome of our previous work on the organic CO-prodrug and the data 
we have at our disposal on CO therapeutic effect, we decided to examine the synergistic effects of 
CO with chemotherapy drug. To do this, we reasoned that by tethering a cytotoxic agent to our 
organic CO-prodrug system, it would be possible to achieve a co-delivery of CO and the cytotoxic 
drug at the target site. This would involve the use of the DAinv reaction as the prodrug activator. 
The general idea is depicted in Fig. 3a. Here, CO is released spontaneously via a retro-
DA/cheletropic reaction after the cycloaddition reaction between a strained alkyne (16) and the 
prodrug (17). Subsequent lactonization will result in the release of the cytotoxic agent. 
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Figure 2. a) Proposed strategy for co-delivery of CO and cytotoxic agent using the 
DAinv as the prodrug activator. b) Examination of the DAinv reaction between the cyclooct-2-
ynol, 21 and the model prodrug, 22. 
To test our concept, we synthesized compounds 21 and 22 (Fig. 2b). For compound 22, to 
allow for real-time monitoring of CO release, we installed the naphthalene moiety to the 
cyclopentadienone as this would generate a fluorophore as a byproduct of the cheletropic reaction. 
 
Scheme 3. i) CHBr3, tBuOK, anhydrous hexane, 5
oC to rt, overnight, 65%, ii) AgClO4, 
acetone/H2O, 10 min, 20oC, 73%, iii) pyridinium-PTSA, DCM, 0oC, 10 min, iv) tBuOK, DMSO, 
20oC, 2 min, 71%, v) PTSA, methanol, rt, 1 h, 93% 
The synthesis of 21 starts with the cycloheptene, 25. The electrophilic “insertion” of the 
dibromocarbene, generated by the reaction between bromoform and potassium tert-butoxide, 
across the double bond of the alkene resulted in the formation of the dibromide 26.28 The dibromide 
adduct, upon treatment with silver perchlorate (AgClO4) in the cosolvent (water/acetone) gave 
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compound 27. This resulted from the silver (1)-assisted rearrangement of the dibromide, forming 
an allylic cation. Nucleophilic attack of this position by the solvent (water) generates the allylic 
alcohol, 27. This type of silver (1)-assisted rearrangement, SN1 Ag-type process is a common 
method used for the synthesis of trans-alkene from exo halobicyclo(n.1.0)alkanes (n ≥ 5) in the 
presence of strong nucleophilic solvents.29-31 Protection of the allylic alcohol was achieved upon 
treatment of 27 with dihydropyran, 28 in the presence of pyridinium-PTSA, in a catalytic amount, 
giving both diastereomers of compound 29 in nearly 1:1 ratio. We observed that, in addition to the 
trans isomers, the cis isomers (both diastereomers) were formed as revealed by the 1H NMR 
spectrum. This is due to isomerization of the trans to the cis isomer in column during purification. 
Hence, we proceeded with the crude product of subsequent synthesis of 29 for the next step. 
Compound 30 was formed in an elimination step involving dehydrobromination of 29 in the 
presence of the strong base, potassium tert-butoxide. Compound 21 was formed after the 
deprotection of 30 in 93% yield (Scheme 3). 
 
Scheme 4. i) pyridine, DCM, 0o C to rt, overnight, 97%, ii) methanol, toluene, reflux, 3 h, 
81%, ii) Et3N, THF/Methanol (1:1), rt, 3 h, 84% 
The synthesis of 22 starts with 32, meldrum’s acid. Acylation of the meldrum’s acid in the 
presence of pyridine, gave the acyl Meldrum’s acid, 33 in quantitative yield. This method was 
reported by Scribner et al.,32 as a general method for the synthesis of β-keto esters. Meldrum’s acid 
has a remarkable acidity and for this reason, it can react with electrophile under mild conditions 
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or in the absence of a strong base. Upon interaction with the pyridine, the mono-anion is generated, 
which then attack the benzoyl chloride (31), ultimately resulting in the formation of the acyl 
Meldrum’s acid. Subsequent treatment of 33, in toluene, with methanol, under reflux, afforded the 
β-keto ester, 34 with evolution of carbon dioxide. The formation of the β-keto ester is facilitated 
by the enolization of the acyl group of the acyl Meldrum’s acid, thus, making it less electrophilic.32 
Finally, condensation of the β-keto ester, 34 with acenaphthylene-1, 2-dione, 35 afforded 
compound 22 in 84% yield (Scheme 4). 
With the synthesis of compounds 21 and 22, we then proceeded to test the click reaction. 
The cycloaddition reaction between compounds 21 and 22 in 30% DMSO/PBS at 37oC generated 
the two fluorescent compounds, 22a and 22b (Fig. 2b). This shows that there was less than 100% 
conversion of the intermediate that resulted from the retro-DA reaction. This is due to the relative 
orientation between compound 21 and compound 22 and thus, dictates the regiochemistry of the 
cycloaddition reaction (fig. 3). Furthermore, the second-order rate constant of the cycloaddition 
reaction between 21 and 22 was determined to be 0.018 M-1s-1. 
 
Figure 3. Manner of approach of diene 22 to dienophile 21. 
After confirming the occurrence of the cycloaddition reaction and subsequent lactonization 
of the model prodrug 22, we were encouraged to synthesize compound 23 which encompasses the 
5-fluoro-2ˈ-deoxyuridine, used as a modality for cancer therapy, as the cytotoxic drug. The 
introduction of the hydrophilic drug to compound 23 helps to overcome the solubility issues 
associated with the model prodrug 22 due to the hydrophobic nature of the naphthalene moiety. 
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To further improve the slow kinetics of the reaction between compounds 21 and 22, we also 
synthesized compound 24 which has the phenyl group of compound 22 replaced with an amide. 
 
Scheme 5. i) chlorobenzene, reflux, 3.5 h, 85%, ii) THF, conc. HCl, rt, 45 min, 92%, iii) 
Et3N, THF/MeOH (1:1), rt, 2 h, 65%, iv) imidazole, TBDMS-Cl, DMF, rt, 1.5 h, 71% 
The synthesis of compound 23 starts with 33. The primary alcohol of the nucleoside, 36 
was selectively protected with tert-butyldimethylsilylchloride (TBS) in the presence of imidazole, 
resulting in the formation of 37. Treatment of the acyl Meldrum’s acid, 33 with 37 gave the β-keto 
ester, 38. The TBS group of the β-ketoester 38 was then removed in acid-catalyzed hydrolysis 
using concentrated hydrochloric acid to give compound 39. Compound 39 was then treated with 
the diketone, acenaphthalene-1, 2-dione, 35 in a condensation reaction to give the final product, 
compound 23 in 65% yield (Scheme 5). 
14 
 
Scheme 6. i) MeOH, toluene, reflux, 4 h, ii) morpholine, DMAP, EDC, DCM, rt, overnight, 
75%, iii) LiOH, MeOH/H2O, rt, 1.5 h, 92%, iv) DMAP, EDC, DMF, rt, 4 h, 56%, v) 
chlorobenzene, reflux, 4 h, 73%, vi) Et3N, THF/MeOH (1:1), rt, 45 min, 60% 
 
Scheme 7. i) benzylalcohol, toluene, reflux, 45 min, 84%, ii) Et3N, THF/MeOH (1:1), rt, 2 
h, 68% 
The synthesis of compound 24 starts with Meldrum’s acid, 32. The nucleophilic attack by 
methanol on the carbonyl of Meldrum’s acid gave the ester of malonic acid, 40 with concomitant 
formation of acetone. Amidation of 40 with morpholine in the presence of the coupling agent, 
EDC, and DMAP (functioning as a nucleophilic catalyst) gave the amide, 41. Basic hydrolysis of 
compound 41 led to the formation 42. Compound 43 was formed from the acylation reaction 
between 42 and Meldrum’s acid in the presence of EDC and DMAP. Nucleophilic attack on the 
carbonyl of compound 43 by the hydroxyl group of the nucleoside, 37 gave compound 44. After 
removal of the TBS group of 44 to afford compound 45, the final compound, 24 was obtained in 
60% yield from the condensation of compound 45 with acenaphthalene-1, 2-dione, 35 (Scheme 
6). 
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Figure 4. a) Click reaction between compounds 21 and 23. b) Click reaction between 
compounds 21 and 24. c) Click reaction between compounds 21 and 47 
Next, we tested the click reaction, first, between compounds 21 and 23, and then between 
compounds 21 and 24 in 30% DMSO/PBS at 37oC. The cycloaddition reaction between 21 and 23 
released CO with the concomitant formation of the two fluorescent, regioisomers 23a and 23b, 
and release of the cytotoxic drug (Fig. 4a). The second order rate constant between compounds 21 
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and 23 in 30% DMSO/PBS at 37oC was determined to be 0.048 M-1s-1. The click reaction between 
compounds 21 and 24, upon incubation in 30% DMSO/PBS at 37oC furnished CO with the 
formation of two fluorescent compounds 24a and 24b resulting from different regiochemistry, and 
release of the cytotoxic drug and morpholine respectively (Fig. 4b). The regiochemistry of the 
click reaction and outcome of the subsequent lactonization, as earlier acknowledged, were due to 
the relative orientation between the diene and dienophile. The second order rate constant between 
compound 21 and compound 24 was determined to be 0.168 M-1s-1. As we expected, the result 
showed higher reaction rate, with 9-fold and 4-fold increase compared to that between 21 and 22, 
and between 21 and 23 respectively. This increased reaction rate between compound 21 and 
compound 24 was presumably due to fine tuning of the electronics of the cyclopentadienone ring 
achieved by the introduction of the amide substituent. This has the effect of decreasing the LUMO 
energy of the diene, thus, narrowing the HOMOdienophile-LUMOdiene energy gap, ultimately 
resulting in higher reaction rate. 
To determine the ratio of the cyclized product, 22a to the uncyclized product, 22b, we 
synthesized compound 47 and monitored the click reaction between 21 and 47 (Fig. 4c) using 1H 
NMR spectroscopy Fig. 13. We used compound 47 instead of 22 for this study because of the 
solubility issue associated with compound 22. Within 2 hrs, we observed the disappearance of the 
methylene peak (5.43 ppm) of compound 47, indicative of the cycloaddition. New resonances 
corresponding to benzylalcohol (BnOH), compound 47a, compound 47b, and the intermediate, the 
byproduct of the retro-DA reaction, at 4.49 ppm, 5.90-5.95 ppm and 6.30 ppm, 5.98-6.00 ppm and 
5.60 ppm, and 6.1 ppm and 5.7 ppm respectively were observed. We noticed that because of the 
chirality of compound 47b at the carbon atom, a, the two methylene protons at carbon a’ are 
diastereotopic, hence the quartet at 5.60 ppm, confirming the formation of the regioisomer 47b. 
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The presence of the BnOH peak confirms the cyclization reaction. After 21 hrs, the ratio of 47a to 
47b is 1:1, and 57% of the cyclized product 47a was obtained. 
We subsequently employed HPLC to test the release of the cytotoxic drug from compound 
24 (100 µM) as induced by 21 (5 mM) in 20% DMSO in PBS at 37oC (Fig. 5). The reaction was 
completed in 220 ± 10 min and afforded the cytotoxic drug in 45 ± 0.4 % as determined from the 
calibration curve.  To ensure that the release is not due to instability of the prodrug, due to the 
susceptibility of the ester linker to hydrolysis, we incubated the prodrug, compound 24 (50 µM) 
for at least 21 h in 20% DMSO in PBS at 37o C. We observed 76 % of the prodrug 24 after 8 h 
Fig. 14. This implies that the release of the drug from compound 24 was mainly triggered by the 
DAinv reaction as the release of the drug was completed in 3.5 h. 
 
 
Figure 5. Drug release profile from compound 24 (100 µM) with 5 mM of 21 in 20% 
DMSO/PBS at 37o C. 
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Figure 6.  Cytotoxicity of Compounds 24 and 21 in mb231. The solution (100 µM) of 
compounds 24 and 21 was diluted to 2, 4, 6, 8, and 10 µM. 
After confirming the release of the cytotoxic drug, we then proceeded to evaluate the 
synergistic effect between CO and the cytotoxic drug. This study was done by one of our 
collaborators at Emory. The cytotoxicity assay was carried out using the human breast tumor cell 
line, mb231. We first assessed the cytotoxic effect of compounds 21 and 24 separately. Compound 
21 showed no decrease in cell viability at 100 µM concentration (figure not shown). However, 
compound 24 showed a 50% decrease in cell viability at 10 µM concentration after 72h treatment 
(Fig. 6). Upon co-treatment of the cells with 10 µM of compound 24 and 100 µM of compound 
21 for 72 h, there was a decrease in cell viability by 30%, although, we did not observe any 
synergistic effect between CO and the cytotoxic drug. Barbara Wegiel et al.,24 demonstrated the 
synergistic effect between CO and the genotoxin, doxorubicin in human prostrate and lung cancer. 
They showed that with low CO concentration in combination with camptothecin or doxorubicin, 
there was an increased synergy between CO and camptothecin or doxorubicin in inducing cell 
death in prostate cancer cell line with an approximate 1000-fold over chemotherapy-alone-treated 
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cells. In addition, they also showed that CO offered protection to normal cells against doxorubicin-
induced cell death while enhancing the killing of tumor cells. Based on this, we posited that the 
lack of synergistic effect of our system might be due to two possible reasons: first, the ratio of CO 
to the cytotoxic agent released might not be the right ratio to elicit any beneficial effect by the 
combo. Although, to the best of our knowledge, there has not been any publication that clearly 
defines the right ratio. Secondly, we reasoned that 5-fluorouracil may not have been the “right” 
drug to use for this evaluation since, with the use of doxorubicin and camptothecin, such 
synergistic effect was clearly demonstrated and observed,24 suggesting that CO can sensitize 
cancer cells only to doxorubicin- or camptothecin-induced DNA damage. 
 
Scheme 8. A different route to the synthesis of trans-alkene 
In our earlier effort to synthesize compound 21, we realized that it could be possible to 
carry out lithium exchange with compound 27, and subsequent protonation would afford 
compound 48. We proceeded to attempt this reaction and not only did we obtained the desired 
product, 48, as a single diastereomer, equatorial isomer as confirmed by 1H NMR, the yield was 
also improved- compound 48 was obtained in an overall 74% yield (Scheme 8). 
2.2 Conclusion 
In conclusion, we have designed and successfully synthesized various organic CO-
prodrugs. We demonstrated the proof of concept and co-delivery of CO and the cytotoxic agent by 
leveraging on the inverse electron-demand Diels Alder reaction as the trigger near physiological 
conditions. We showed that CO release rate and delivery of the cytotoxic agent can be tuned by 
manipulating the electronics of our prodrug system. Furthermore, cell viability studies using 
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human breast cancer cell lines, mb231 showed significant inhibition of tumor growth, however, 
with no synergy between CO and the cytotoxic drug.  
2.3 Experimental  
2.3.1 General Information 
All reagents and solvents were of reagent grade. Column chromatography was carried out 
using flash silica gel (Sorbent 230–400 mesh) and P-2 Gel (Bio-Gel, particle size range 45- 90 
μm). TLC analysis was conducted on silica gel plates (Sorbent Silica G UV254). NMR spectra 
were recorded at 400 MHz for 1H and 100 MHz for 13C on an Avance Bruker instrument. 
Chemical shifts (δ values) and coupling constants (J values) are given in ppm and hertz, 
respectively, using the respective solvent (1H NMR, 13C NMR) as the internal reference. 
Reagents: tBuOK- potassium tert-butoxide, THF- tetrahydrofuran, Et3N- triethylamine, 
AgClO4- silver perchlorate, TBDMS-Cl- tertbutyldimethylsilylchloride, AcOH- acetic acid, 
PTSA-p-Toluenesulfonic acid, EDC-1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, DMAP-4-
dimethylaminopyridine, Et3N-triethylamine. 
2.3.2 Synthesis of 26 
 
Compound 26: 8, 8-dibromodicyclo[5.1.0].34 5.03g of 25 (52.3 mmol), 11.7g of tBuOK 
(104.2 mmol), and 12 ml of anhydrous hexane were introduced into a dried round-bottom flask 
under argon. The flask placed in an ice/salt bath (<-5oC), and the solution was vigorously stirred 
for 30 min and then 19.8g of bromoform (78.3 mmol) were added dropwise. Once the addition 
was complete, the mixture was warmed to room temperature overnight under argon and with 
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vigorous stirring. 40 ml of water was subsequently added followed by the addition of 1M HCl. 
The reaction mixture was extracted with hexane. The combined organic layer was washed with 
brine, dried with anhydrous Na2SO4, and concentrated. The crude product was purified by column 
chromatography (silica gel, hexane) to afford 26 as a colorless liquid in 65% yield, 1H NMR 
(CDCl3), 2.25-2.31 (m, 2H), 1.81-1.94 (m, 3H), 1.69-1.77 (m, 2H), 1.34-1.45 (m, 2H), 1.13-1.27 
(m, 3H). 
2.3.3 Synthesis of 27 
 
Compound 27: (E)-2-bromocyclooct-2-en-1-ol.35 To a solution of AgClO4 (2.11g, 7.8 
mmol) in 5 ml of acetone/H2O (9:1) was added 26 (2.11g, 7.8 mmol) dropwise at 20
oC and the 
reaction mixture was stirred for 10 min. Water was added to the mixture and the silver salt was 
filtered off under suction. The filtrate was extracted with EA. The combined organic layer was 
washed with brine and the silver salt was again filtered under suction. The filtrate was dried with 
anhydrous Na2SO4, and concentrated. The crude product was purified by column chromatography 
(silica gel, hexane/EA (20:1)) to afford 27 as a white solid in 73% yield, 1H NMR (CDCl3), 6.07 
(dd, J = 12 .0 Hz, 4.0 Hz, 1H), 4.17 (dd, J = 8.0 Hz, 4.0 Hz, 1H), 2.88 (s, 1H), 2.58-2.69 (m, 1H), 
2.23-2.29 (m, 1H), 1.95-1.99 (m, 2H), 1.62-1.88 (m, 4H), 1.40-1.51 (m, 4H), 0.74-0.82 (m, 1H) 
2.3.4 Synthesis of 28 
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Compound 29: (Z)-2-((2-bromocyclooct-2-en-1-yl)oxy)tetrahydro-2H-pyran.36 To a 
solution of 27 (1.49g, 7.2 mmol) in 8 ml of DCM was added pyridinium-PTSA (0.09g, 0.03 mol%). 
To this solution was added 28 (0.91g, 10.8 mmol) dropwise at 0oC. The reaction mixture was 
stirred at this temperature for 10 min. Water was added to the mixture and extracted with DCM. 
The combined organic layer was washed with brine, dried with anhydrous Na2SO4, and 
concentrated. The crude product was used in the next step without purification. 
2.3.5 Synthesis of 30 
 
Compound 30: 2-(cyclooct-2-yn-1-yloxy)tetrahydro-2H-pyran.36 To a stirring solution 
of t-BuOK (0.47g, 4.2 mmol) in 10 ml of anhydrous DMSO was added a solution of 29 (0.31g, 
1.1 mmol) in 1 ml of anhydrous DMSO at 20oC. After adding, the reaction was immediately 
quenched by pouring the reaction mixture into an ice solution of 1 ml of acetic acid. The mixture 
was extracted with EA and the combined organic layer was washed with brine, dried with 
anhydrous Na2SO4, and concentrated. The crude product was purified by column chromatography 
(silica gel, hexane/EA (300:1)) to afford 30 as an colorless oil in 71% yield, 1H NMR (CDCl3), 
4.69-4.71 (t, 1H), 4.38-4.43 (m, 1H), 3.96-4.01 (m, 1H), 3.51-3.56 (m, 1H), 2.24-2.33 (m, 1H), 
2.11-2.20 (m, 2H), 1.91-2.03 (m, 2H), 1.80-1.89 (m, 3H), 1.66-1.79 (m, 2H), 1.49-1.64 (m, 5H), 
1.36-1.45 (m, 1H), 2.25-2.32 (m, 1H). 
2.3.6  Synthesis of 21 
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Compound 21: cyclooct-2-yn-1-ol.36 To a solution of 30 (0.17g, 0.8 mmol) in 10 ml of 
methanol was added PTSA (0.008g, 0.04 mmol) at room temperature. The reaction mixture was 
stirred continuously at room temperature for 1h 45 min. After completion of the reaction as 
indicated by TLC, the methanol was removed by rotavap, and water was added to the product 
mixture and extracted with EA. The combined organic layer was washed with brine, dried with 
anhydrous Na2SO4, and concentrated. The crude product was purified by column chromatography 
(silica gel, hexane/EA (100:1)) to afford 21 as a colorless oil in 93% yield, 1H NMR (CDCl3), 
4.47-4.50 (t, 1H), 2.25-2.32 (m, 1H), 2.12-2.23 (m, 1H), 1.87-2.01 (m, 2H), 1.51-1.83 (m, 6H). 
2.3.7 Synthesis of 33 
 
Compound 33: 2, 2-dimethyl-5-(2-phenylacetyl)-1, 3-dioxane-4, 6-dione.27 To a solution 
of 32 (2.3g, 15.6 mmol) in 10 ml of DCM was added 2.5 ml of pyridine dropwise at 0oC. To this 
mixture was added 2.1 ml of 31 dropwise. The mixture was stirred at 0oC for 1 h and then warmed 
to room temperature and stirred overnight. To the product mixture was added I M HCl and 
extracted with DCM. The combined organic layer was washed with brine, dried with anhydrous 
Na2SO4 and concentrated. The crude product was purified by column chromatography (silica gel, 
hexane/EA (1:1)) to afford 33 as a white solid in 97% yield, 1H NMR (CDCl3), 15.35 (s, 1H), 7.42 
(s, 1H), 7.40 (s, 1H), 7.36-7.37 (t, 1H), 7.35 (s, 1H), 7.30-7.33 (m, 1H), 4.45 (s, 1H), 1.74 (s, 6H). 
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2.3.8 Synthesis of 34 
 
Compound 34: methyl 3-oxo-4-phenylbutanoate.27 To a solution of 33 (3.20g, 0.01 
mmol) in 10 ml of toluene was added methanol (0.78g, 0.02 mmol). the resulting mixture was 
heated under reflux for 3h. The reaction mixture was cooled to room temperature and concentrated. 
The crude product was purified by column chromatography (silica gel, Hexane/EA (2:1)) to afford 
34 in 81% yield. 1H NMR (CDCl3), 7.23-7.38 (m, 5H), 3.84 (s, 1H), 3.72 (s, 3H), 3.48 (s, 1H). 
2.3.9 Synthesis of 22 
 
Compound 22: methyl 8-oxo-9-phenyl-8H-cyclopenta[a]acenaphthylene-7-
carboxylate.27 To a solution of 34 (0.14g, 0.80 mmol) in 2 ml of THF/MeOH (1:1) was added 
trimethylamine (0.12g, 1.21 mmol) and 35 (0.14g, 0.80 mmol) at room temperature. After 30 min, 
the color of the reaction turned green. The reaction was stirred for 3h. The precipitate was filtered, 
washed several times with methanol and then dried to obtain 22 as a dark solid in 84% yield. 1H 
NMR (CDCl3), 8.77 (d, J = 7.2 Hz, 1H), 8.09-8.05 (m, 2H), 7.94 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 
7.2 Hz, 2H), 7.80 (t, J = 7.6 Hz, 1H), 7.63 (t, J = 8.0 Hz, 1H), 7.54 (t, J = 8.0 Hz, 2H), 7.47 (t, J = 
7.6 Hz, 1H), 4.03 (s, 3H). 
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2.3.10 Synthesis of 37 
 
Compound 37: 1-(5-(((tert-butyldimethylsilly)oxy)methyl)-4-
hydroxytetrahydrofuran-2-yl)-5-fluoropyrimidine-2, 4(1H, 3H)-dione.37 To a solution of 36 
(1.20g, 4.87 mmol) in 5 ml of DMF was added imidazole (0.99g, 0.01 mmol) and TBDMS-Cl 
(0.77g, 5.12 mmol) at room temperature the reaction mixture was stirred for 1.5 h. To the product 
mixture was added water and extracted with DCM. The combined organic layer was washed with 
brine, dried with anhydrous Na2SO4 and concentrated. The crude product was purified by column 
chromatography (silica gel, hexane/EA (4:1)) to afford 37 as a white solid in 71% yield. 1HNMR 
(CDCl3), 8.09 (d, J = 8.0 Hz, 1H), 6.37-6.41 (t, 1H), 4.46-4.48 (t, 1H), 4.12 (s, 1H), 3.94 (d, J = 
12.0 Hz, 1H), 3.85 (d, J = 12.0 Hz, 1H), 2.44-2.50 (m, 1H), 2.09-2.16 (m, 1H), 0.96 (s, 9H), 0.11 
(s, 6H). 
2.3.11 Synthesis of 38 
 
Compound 38: 2-(((tert-butyldimethylsilly)oxy)methyl-5-(5-fluoro-2, 4-dioxo-3,  4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl 3-oxo-4-phenylbutanoate. To a solution of 
33 (0.37g, 1.41 mmol) in 5 ml of chlorobenzene was added 37 (0.34g, 0.9 mmol) at room 
temperature. The reaction mixture was heated under reflux for 3.5 hrs. The crude product was 
concentrated and purified by column chromatography (silica gel, DCM/MeOH (40:1)) to afford 
38 as a white solid in 91% yield. 1H NMR (CDCl3), 11.86 (s, 1H), 10.25 (d, J = 4.0 Hz, 1H), 8.0 
(d, J = 8.0 Hz, 1H), 7.25-7.36 (m, 4H), 7.20 (s, 1H), 6.31-6.35 (t, 1H), 5.26 (d, J = 4.0 Hz, 1H), 
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3.90 (s, 2H), 3.81 (s, 2H), 3.53 (s, 2H), 2.42-2.48 (m, 1H), 2.07-2.14 (m, 1H), 0.92 (s, 9H), 0.13 
(s, 6H), 13C NMR (CDCl3), 18.3, 25.9, 47.9, 50.3, 76.3, 76.9, 77.5, 85.4, 85.7, 127.5, 128.9, 129.6, 
132.9, 149.4, 166.8, 200.3, HRMS (ESI): calculated for; C25H33FN2O7Si 520.2075, found; 
543.1939 [M+Na]+. 
2.3.12 Synthesis of 39 
 
Compound 39: 5-(5-fluoro-2, 4-dioxo-3, 4-dihydropyrimidin-1(2H)-yl)-2-
(hydroxymethyl)tetrahydrofuran-3-yl 3-oxo-4-phenylbutanoate. To a solution of 38 (0.53g) in 
about 5 ml of THF was added conc. HCl in drops until the solution became cloudy. The reaction 
mixture was stirred at room temperature for 45 min. the reaction was quenched with water and 
extracted with EA. The combined organic layer was washed with brine, dried with anhydrous 
Na2SO4 and concentrated. The crude product was purified by column chromatography (silica gel, 
DCM/MeOH (20:1)) to afford 38 as white a solid in 98% yield. 1H NMR (CDCl3), 2.28-2.41 (m, 
2H), 3.54 (s, 2H), 3.81 (s, 2H), 3.86 (s, 2H), 4.09 (s, 1H), 5.34 (d, J = 8.0 Hz, 1H), 6.22-6.26 (t, 
1H), 7.20 (d, J = 4.0 Hz, 2H),  7.24-7.30 (t, 1H), 7.32-7.36 (t, 2H), 8.08 (d, J = 8.0 Hz, 1H), HRMS 
(ESI): calculated for; C19H19FN2O7 406.1176, found; 429.1050 [M+Na]
+. 
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2.3.13 Synthesis of 23 
 
Compound 23: 5-(5-fluoro-2, 4-dioxo-3, 4-dihydropyrimidin-1(2H)-yl)-2-
(hydroxymethyl)tetrahydrofuran-3-yl 8-oxo-9-phenyl-8H-cyclopenta[a]acenaphthylene-7-
carboxylate. To a solution of 39 (0.22g, 0.54 mmol) in 2 ml of THF/MeOH (1:1) was added 
trimethylamine (0.08g, 0.81 mmol) and 35 (0.09g, 0.54 mmol) at room temperature. After 30 min, 
the color of the reaction turned green. The reaction was stirred for 2h. The precipitate was filtered, 
washed several times with methanol and then dried to obtain 23 as a dark solid in 65% yield. 1H 
NMR (DMSO-d6), 1.91 (s, 1H), 1.99 (s, 1H), 3.77 (s, 2H), 4.25 (s, 1H), 4.39 (s, 1H), 5.50-5.56 
(m, 1H), 6.31-6.37 (m, 1H), 7.50-7.53 (t, 1H), 7.57-7.61 (m, 2H), 7.75-7.77 (m, 3H), 7.87-7.92 
(m, 1H), 7.99-8.13 (m, 2H), 8.27-8.31 (t, 1H), 8.61 (d, J = 8.0 Hz, 1H), 11.96 (s, 1H), HRMS 
(ESI): calculated for; C31H21FN2O7 552.1333, found; 575.0784 [M+Na]
+. 
 
2.3.14 Synthesis of 40 
 
Compound 40: 3-methoxy-3-oxopropanoic acid. To a solution of 32 (5.02g, 34.8 mmol) 
in 10 ml of toluene was added methanol (2.22g, 69.3 mmol) at room temperature. The resulting 
mixture was heated under reflux for 4h. After completion of the reaction as monitored by TLC, 
the reaction was cooled to room temperature and then concentrated. The crude product was used 
directly in the next step. 
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2.3.15 Synthesis of 41 
 
Compound 41: methyl 3-morpholino-3-oxopropanoate. To a solution of 40 (4.10g, 34.7 
mmol) in 10 ml of DCM was added morpholine (4.54g, 52.1 mmol) and DMAP (5.09g, 41.6 mmol) 
at room temperature. The reaction mixture was cooled to 0oC and EDC (7.99g, 41.6 mmol) was 
added portion-wise for about 5 min. The reaction mixture was then warmed to room temperature 
and stirred continuously overnight. The reaction was quenched with 1M HCl and then extracted 
with DCM. The combined organic layer was washed with brine, dried with anhydrous Na2SO4, 
and then concentrated. The crude product was purified by column chromatography (silica gel, 
Hexane/ EA (2:1)) to afford the desired product as a white solid in 75% yield. 1H NMR (CDCl3), 
3.71 (s, 3H), 3.63-3.66 (m, 6H), 3.40-3.43 (m, 4H), 13C NMR (CDCl3), 167.9, 164.4, 77.4, 76.8, 
66.6, 66.5, 52.5, 40.8, 42.2, 40.8 
2.3.16 Synthesis of 42 
 
Compound 42: 3-morpholino-3-oxopropanoic acid. To a solution of 40 (2.11g, 11.2 
mmol) in 10 ml of methanol/H2O (2:1) was added LiOH (0.40g, 16.7 mmol). The resulting mixture 
was stirred at room temperature for 1.5h. After completion of the reaction as determined by TLC, 
the reaction mixture was extracted with EA. To the aqueous layer was added amberlite ion-
exchange resin and the mixture was stirred for 30 min. The mixture was filtered under suction and 
the filtrate was concentrated to afford 42 as a white solid in 92% yield. 1H NMR (CDCl3), 3.70-
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3.77 (m, 6H), 3.49-3.52 (t, 2H), 3.41 (s, 2H), 13C NMR (CDCl3), 35.2, 42.5, 45.7, 66.2, 66.5, 76.7, 
77.4, 167.6, 168.1, HRMS (ESI): calculated for; C7H11NO4 173.0688, found; 174.0753 [M+H]
+. 
2.3.17 Synthesis of 43 
 
Compound 43: 2, 2-dimethyl-5-(3-morpholino-3-oxopropanoyl)-1, 3-dioxane-4, 6-
dione. To a solution of 42 (1.35g, 77.9 mmol) in 5 ml of DMF was added DMAP (1.17g, 9.5 
mmol) and EDC (1.99g, 10.3 mmol) under argon at room temperature. The reaction mixture was 
cooled to 0oC and a solution of 32 (1.17g, 8.1 mmol) in 2 ml of DMF was added drop-wise to the 
reaction. The reaction was completed after 4 hrs as determined by TLC. The reaction was quenched 
with 1M HCl and then extracted with DCM. The combined organic layer was washed with brine, 
dried with anhydrous Na2SO4, and concentrated. The crude product was purified by column 
chromatography (silica gel, acetone) to afford 43 as a white solid in 56% yield.  1H NMR (Acetone-
d2), 4.13 (s, 2H), 3.82 (s, 1H), 3.60-3.70 (m, 8H), 1.63 (s, 6H), HRMS (ESI): calculated for 
C13H17NO7 300.1039, found; 300.1063. 
2.3.18 Synthesis of 44 
 
Compound 44: 2-(((tert-butyldimethylsilyl)-5-(5-fluoro-2, 4-dioxo-3, 4-
dihydropyrimidin-1 (2H)-yl)tetrahydrofuran-3-yl 5-morpholino-3, 5-dioxopentanoate. To a 
solution of 43 (0.18g, 0.5 mmol) in 3 ml of chlorobenzene was added 37 (0.23g, 0.7 mmol) at 
room temperature. The reaction mixture was heated under reflux for 4hrs. The crude product was 
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concentrated and purified by column chromatography (silica gel, DCM/MeOH (40:1)) to afford 
44 as yellow solid in 73% yield. 1H NMR (CDCl3), 14.83 (s, 1H), 9.68 (s, 1H), 8.0-8.03 (t, 1H), 
6.33-6.37 (t, 1H), 5.29-5.33 (t, 1H), 4.18 (d, J = 12.0 Hz, 1H), 3.90-3.96 (t, 2H), 3.71 (s, 7H), 3.65 
(d, J = 8.0 Hz, 2H), 3.45-3.47 (t, 1H), 3.28 (s, 1H), 2.49-2.54 (m, 1H), 2.12-2.19 (m, 1H), 0.93 (s, 
9H), 0.15 (s, 6H), 13C NMR (CDCl3), 18.3, 25.9, 38.2, 42.3, 46.7, 48.7, 48.7, 63.7, 66.5, 66.7, 76.7, 
77.4, 85.4, 85.6, 149.0, 164.6, 166.7, 196.54, HRMS (ESI): calculated for C24H36FN3O9Si 
558.2238, found; 558.2273. 
2.3.19 Synthesis of 45 
 
Compound 45: 5-(5-fluoro-2, 4-dioxo-3, 4-dihydropyrimidin-1(2H)-yl)-2-
(hydroxymethyl)tetrahydrofuran-3-yl 5-morpholino-3, 5-dioxopentanoate. To a solution of 
44 (0.53g) in about 5 ml of THF was added conc. HCl in drops until the solution became cloudy. 
The reaction mixture was stirred at room temperature for 45 min. The reaction was quenched with 
water and extracted with EA. The combined organic layer was washed with brine, dried with 
anhydrous Na2SO4 and concentrated. The crude product was used directly in the next step. 
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2.3.20 Synthesis of 24 
 
Compound 24: 5-(5-fluoro-2, 4-dioxo-3, 4-dihydropyrimidin-1(2H)-yl)-2-
(hydroxymethyl)tetrahydrofuran-3-yl-9-(morpholine-4-carbonyl)-8-oxo-8H-
cyclopenta[a]acenaphthylene-7-carboxylate. To a solution of 45 (0.82g, 1.85 mmol) in 2 ml of 
THF/MeOH (1:1) was added trimethylamine (0.28g, 2.77 mmol) and 35 (0.33g, 1.84 mmol) at 
room temperature. After 30 min, the color of the reaction turned green. The reaction was stirred 
for 45 min. The precipitate was filtered, washed several times with methanol and then dried to 
obtain 24 as a dark solid in 60% yield. 1H NMR (DMSO-d6), 11.92 (s, 1H), 8.95 (s, 1H), 8.19-8.30 
(m, 3H), 7.83-7.90 (m, 3H), 6.33 (s, 1H), 5.44-5.54 (m, 2H), 4.25 (s, 1H), 1 3.53-3.57 (m, 10H), 
13C NMR (DMSO-d6), 37.5, 39.4, 39.8, 39.9, 40.2, 40.4, 40.6, 42.4, 47.3, 61.9, 66.6, 67.2, 76.1, 
85.0, 85.5, 124.5, 124.8, 125.1, 128.2, 129.5, 129.9, 132.1, 139.5, 141.8, 145.4, 149.6, 155.9, 
157.4, 157.6, 161.4, 167.6, 194.1, HRMS (ESI): calculated for; C30H28FN3O9 594.1843, found; 
595.3818 [M+H]+. 
2.3.21 Synthesis of 46 
 
Compound 46: benzyl 3-oxo-4-phenylbutanoate. To a solution of 33 (505 mg, 1.92 
mmol) in 5 ml of toluene was added benzylalcohol (420 mg, 3.88 mmol). The reaction mixture 
was refluxed for about 45 min and allowed to cool to room temperature after completion of the 
reaction as indicated on TLC. The crude product was concentrated on rotavap and then purified by 
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column chromatography (silica gel, Hexane/EA (10:1)) to afford 46 as a white solid in 84% yield. 
1H NMR (CDCl3), 3.54 (s, 2H), 3.84 (s, 2H), 5.19 (s, 2H), 7.21 (d, J = 8.0 Hz, 2H), 7.33-7.41 (m, 
8H); 13C NMR (CDCl3), 48.3, 50.1, 67.2, 76.8, 77.5, 127.4, 128.4, 128.5, 128.7, 128.9, 129.6, 
133.2, 135.3, 166.9, 200.3, HRMS (ESI): calculated for; C17H16O3 268.1099, found; 291.0997 
[M+Na]+. 
2.3.22 Synthesis of 47 
 
Compound 47: benzyl 8-oxo-9-phenyl-8H-cyclopenta[a]acenaphthylene-7-
carboxylate. To a solution of 46 (132 mg, 0.49 mmol) in 5 ml of THF/MeOH (1:1) was added 
triethylamine (75.6 mg, 0.75 mmol). To this mixture was added 35 (90.4 mg, 0.49 mmol). The 
reaction mixture was stirred at room temperature for about 2h. The crude product was concentrated 
on rotavap and then dissolved in 5 ml of acetic acid anhydride. The resulting mixture was stirred 
at room temperature, followed by the addition of few drops of concentrated HCl. This resulted to 
the formation of black precipitates. The product mixture was filtered under suction and the residue 
was washed several times with MeOH to afford 47 as a black solid in 68% yield. 1H NMR (DMSO-
d6), 5.43 (s, 2H), 7.38-7.60 (m, 8H), 7.72-7.81 (m, 4H), 8.00 (d, J = 4.0 Hz, 1H), 8.10 (d, J = 8.0 
Hz, 1H), 8.24 (d, J = 8.0 Hz, 1H), 8.55 (d, J = 8.0 Hz, 1H), 13C NMR (DMSO-d6), 39.4, 39.8, 39.9, 
40.2, 40.4, 40.6, 66.1, 109.7, 121.9, 128.6, 128.8, 129.0, 129.2, 129.5, 129.7, 130.0, 130.5, 132.1, 
136.7, 144.8, 150.7, 161.8, 169.6, 169.7, 196.0, 196.7,  HRMS (ESI): calculated for; C17H16O3 
414.1256, found; 437.1172 [M+Na]+. 
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2.3.23 Synthesis of 48 
 
Compound 49: (E)-cyclooct-2-en-1-ol.36 To a solution of 27 (0.66g, 3.20mmol) in about 
5 ml of anhydrous THF under argon at -78oC was added butyllithium (5ml) dropwise for about 15 
min.  the reaction mixture was warmed to room temperature and stirred for 1.5 h. the reaction was 
quenched with ammonium chloride solution and the product mixture was extracted with EA. The 
combined organic layer was washed with brine, dried with anhydrous Na2SO4 and concentrated. 
The crude product was purified by column chromatography (silica gel, hexane/EA (20:1)) to afford 
48 as a colorless liquid in 74% yield. 1HNMR (CDCl3), 0.71-0.79 (m, 1H), 0.85-0.93 (m, 1H), 
1.34-1.54 (m, 2H), 1.73-2.00 (m, 4H), 2.12-2.19 (m, 2H), 2.37-2.42 (m, 1H), 4.23-4.29 (m, 1H), 
5.54 (dd, J = 16.0 Hz, 4.0 Hz, 1H), 5.62-5.65 (m, 1H). 
2.4 Click Reaction between 21 and 22 
 
21 (107 mg, 0.32 mmol) and 22 (61.8 mg, 0.49 mmol) were dissolved in 20 ml of 
ACN/DMSO (1:1) at room temperature. The reaction mixture was heated to about 50 oC for about 
45 min to dissolve 22. The reaction mixture was cooled to room temperature, and thereafter 0.7 
ml of PBS was added. The reaction mixture was stirred overnight at room temperature. To the 
product mixture was added water and extracted with EA. The combined organic layer was washed 
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with brine, dried with anhydrous Na2SO4 and concentrated. The crude product was purified by 
column chromatography (silica gel, Hexane/EA (20:1)) to afford the desired products as two 
regioisomers (22a and 22b) in 37% and 22% yields respectively. 1H NMR (CDCl3), 22a, 9.12 (d, 
J = 4.0 Hz, 1H), 7.94 (d, J = 8.0Hz, 1H), 7.75-7.83 (m, 2H), 7.60-7.63 (m, 3H), 7.44-7.46 (m, 1H), 
7.30-7.36 (m, 2H), 6.37 (d, J = 8.0 Hz, 1H), 5.63-5.67 (m, 1H), 2.71-2.80 (m, 2H), 2.60-2.68 (m, 
1H), 2.01-2.05 (m, 1H), 1.84-1.90 (t, 1H), 1.44-1.53 (m, 2H), 1.28 (s, 2H), 1.01-1.12 (m, 1H); 22b, 
7.83 (d, J = 8.0 Hz, 1H), 7.73 (dd, J = 12.0 Hz, 8.0 Hz, 2H), 7.57-7.63 (m, 4H), 7.46 (s, 1H), 7.36-
7.39 (m, 1H), 7.22-7.24 (t, 1H), 6.03 (d, J = 8.0 Hz, 1H), 5.30 (s, 1H), 4.15 (s, 3H), 2.85-2.91 (m, 
1H), 1.97 (s, 2H), 1.66-1.83 (m, 5H), 0.91 (s, 1H). 
2.5 Click Reaction between 21 and 24 
 
21 (24.7 mg, 0.23 mmol) and 24 (78.3 mg, 0.13 mmol) were dissolved in 10 ml of 
DMSO/PBS (30 % DMSO) at room temperature. The reaction mixture was stirred at room 
temperature for 4h. To the product mixture was added water and extracted with EA. The combined 
organic layer was washed with brine, dried with anhydrous Na2SO4 and concentrated. The crude 
product was purified by column chromatography (silica gel, Hexane/EA (5:1)) to afford the desired 
products as two regioisomers (24a and 24b) in 43% and 32% yields respectively. 1H NMR 
(CDCl3), 24a, 9.114-9.17 (m, 1H), 7.98-8.02 (m, 2H), 7.90-7.93 (t, 1H), 7.78-7.82 (m, 1H), 7.67-
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7.71 (m, 1H), 5.61-5.67 (m, 1H), 4.07-4.09 (t, 2H), 3.87-3.97 (m, 2H), 3.37-3.53 (m, 2H), 3.08-
3.28 (m, 2H), 2.74-2.86 (m, 3H), 1.81-2.07 (m, 4H), 1.38-1.55 (m, 2H), 13C NMR (CDCl3),  20.9, 
24.5, 26.6, 29.4, 39.0, 41.8, 46.7, 66.6, 66.8, 76.7, 82.9, 121.0, 122.7, 127.9, 128.3, 128.4, 129.8, 
130.4, 132.6, 133.4, 133.6, 135.0, 136.6, 137.0, 149.5, 167.4, 169.9, HRMS (ESI): calculated for 
C28H25NO4 440.1817, found; 440.1845, 24b, 9.47 (s, 1H), 9.00 (d, J = 8.0 Hz, 1H), 8.10 (dd, J = 
8.0Hz, 4.0Hz, 1H), 8.03 (d, J = 8.0Hz, 2H), 7.87 (d, J = 4.0Hz, 1H), 7.71-7.79 (m, 2H), 6.22-6.25 
(m, 1H), 5.90-5.93 (m, 1H), 5.64-5.68 (m, 1H), 4.35-4.38 (m, 1H), 23.91-3.99 (m, 2H), 3.62 (d, J 
= 4.0Hz, 1H), 2.85-2.94 (m, 2H), 2.53-2.68 (m, 3H), 1.95-1.99 (m, 3H), 1.83-1.90 (m, 3H), 13C 
NMR (CDCl3), 20.5, 24.1, 25.9, 29.1, 37.3, 37.4, 61.7, 76.9, 76.9, 82.8, 84.9, 85.3, 85.4, 117.3, 
121.8, 123.0, 124.3, 124.6, 127.6, 128.1, 128.5, 128.7, 128.9, 129.8, 131.4, 131.5, 131.9, 132.1, 
132.9, 135.9, 137.0, 139.6, 148.9, 149.9, 157.0, 167.9, 169.6, calculated for C33H27FN2O8 
598.1751, found; 598.2651  
2.6 Kinetics Studies 
2.6.1 The second order rate constants between 22, 23, 24 and 21 
The fluorescent property of the cycloaddition products 22a, 22b, 23a, 23b, 24a, and 24b 
greatly facilitates the determination of the second order reaction rate constants between 22, 23, 24 
and 21 (30 % DMSO/PBS, 37 oC). Briefly, the second order reaction was treated as first order 
reaction by using excessive amount of 21 (> 20-fold), and the obtained k’ was plotted against the 
concentration of 21 used. The obtained slope is the second order reaction rate constant between 
22, 23, 24 and 21 (Figures 8, 10, and 12) 
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2.6.2 Determination of the reaction rate constant between 21 and 22 
               
       
Figure 7, The pseudo first order reaction between 21 and 22: a) 21 (10 mM) + 22 (20 
µM); b) 21 (15 mM) + 22 (20 µM); c) 21 (20 mM) + 22 (20 µM); d) 21 (25 mM) + 22 (20 µM). 
 
 
Figure 8, Plot of the obtained k’ against the concentration of 21 used. The second order 
reaction rate constant k = 0.018 M-1s-1. 
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2.6.3 Determination of the reaction rate constant between 21 and 23 
        
       
Figure 9, The pseudo first order reaction between 21 and 23: a) 21 (500 µM) + 23 (50 
µM); b) 21 (750 µM) + 23 (50 µM); c) 21 (1 mM) + 23 (50 µM); d) 21 (1.25 mM) + 23 (50 
µM); 
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Figure 10, Plot of the obtained k’ against the concentration of 21 used. The second order 
reaction rate constant k = 0.048 M-1s-1. 
2.6.4 Determination of the reaction rate constant between 21 and 24 
          
           
Figure 11, The pseudo first order reaction between 21 and 24: a) 21 (500 µM) + 24 (50 µM); b) 
21 (750 µM) + 24 (50 µM); c) 21 (1 mM) + 24 (50 µM); d) 21 (1.25 mM) + 24 (50 µM); 
y = 0.0477x + 2E-05
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Figure 12, Plot of the obtained k’ against the concentration of 21 used. The second order 
reaction rate constant k = 0.168 M-1s-1. 
2.7 Cytotoxic Studies 
Raw 264.7 cells were seeded in 96-well plates and cultured in Dulbecco’s Modified Eagle’s 
medium (DMEM) supplemented with 10 % fetal bovine serum (FBS) and 1 % 
penicillin/streptomycin at 37 oC under 5 % CO2 for 24 h. then Raw 264.7 cells were incubated in 
DMEM containing the vehicle (1 % DMSO) and compound 24 (0-10 µM) for 24 h. After removal 
of the media, 150 µL of DMEM containing 10 µL (Cell Counting Kit-8 CCK-8) was added to each 
well and the cells were incubated for another 3 h at 37 oC. the absorbance at 450 nm was then 
measured by using a PerkinElmer 1420 multi-label counter. The cell viability was measured and 
results were normalized to the vehicle group. The experiment was triplicated and the results are 
expressed as mean ± standard error of the mean (SEM, n = 3). 
2.8 1H NMR Studies for the Click Reaction between 21 and 47 
To a solution of 47 (8.20 mg, 0.02mmol) in 3 ml of DMSO-d6 was added 21 (7.24 mg, 0.06 
mmol). The resulting solution was incubated at 37 oC and the 1H NMR was taken at different time 
point. As shown in Fig. 13 after 21 h, the ratio of 47a to 47b is 1:1 and 57% of the cyclized product 
47a was obtained. 
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Figure 13. 1H NMR studies for the click reaction between 21 and 47 in DMSO-d6 at 
37oC.  
2.9 Drug Release Experiment 
Drug release was induced by the addition of 21 (5 mM) to compound 24 (100 µM) in 20% 
DMSO in PBS at 37o C. HPLC was used to monitor drug release at different time point. Each 
experiment was triplicated. Drug stoichiometry was measured using a calibration curve. The 
concentration of the released drug was obtained by converting the peak area at a given time to 
concentration using the slope of the calibration curve. 
Different concentrations of compound 24, 30, 60, 90, 120 and 150 µM, in 20% DMSO in 
PBS at room temperature were prepared and used to run the HPLC experiment. Each experiment 
was triplicated. The calibration curve was plotted using the peak areas obtained from the HPLC 
experiment against concentrations Fig 14. 
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Figure 14. Calibration curve for the drug (5-fluoro-2’-deoxyuridine). 
2.10 Stability studies for compound 24 
50 µM of compound 24 in 20% DMSO in PBS was incubated at 37 oC and the HPLC 
experiment was run at the different time point. The peak areas were plotted against time Fig. 15.  
 
Figure 15. Stability curve for compound 24 
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3 KINETIC AND SPECTROSCOPIC CHARACTERIZATION OF DIFFERENT 
ORGANIC CO PRODRUGS 
In furtherance of our effort on the advancement of the medicinal chemistry work on the 
development of organic CO prodrugs, our lab has developed various prodrugs of CO that release 
CO based on an intramolecular Diels-Alder reaction. These prodrugs were synthesized by Dr. Ji 
Xingyue. I only did the kinetic and spectroscopic characterization of these compounds. 
3.1 Results and Discussion 
To determine the kinetics and fluorescence quantum yield, our lab designed and developed 
compounds with the general structure shown in Table 1 BW-CO-107, which, under physiological 
conditions, undergo intramolecular cycloaddition reaction to generate an intermediate that 
spontaneously releases CO and forms a fluorophore via a cheletropic reaction. From the results 
shown in Table 1, CO release rates vary with the ring size of the cyclized products, BW-CP-107. 
For instance, BW-CO-101 and BW-CO-102, each forming a five-membered ring lactam, have 
half-life of 1.9 min compared to BW-CO-103 and BW-CO-104, each forming a six-membered 
ring lactam, with half-lives of 72 min and 372 min respectively. The ease of compounds BW-CO-
107 to undergo cycloaddition reaction to release CO under mild condition such as physiological 
conditions in contrast with the vigorous conditions required for that between an alkyne and 
cyclopentadienone was presumably due to entropic factors. This was displayed in the release rate 
for BW-CO-102, with TBDPS group in place of the alkyne terminal hydrogen, which happens to 
be similar with that for BW-CO-101. The CO release rate for BW-CO-105 which leads to 
formation of a lactone is much slower (t1/2, > one week) compared to BW-CO-101 which forms a 
lactam. The slow kinetics of BW-CO-106 was due to the formation of hydrogen bond between the 
amide hydrogen and the carbonyl of the cyclopentadienone which locked the molecule in an 
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unfavourable conformation for the cycloaddition reaction.33 The CO release rate for BW-CO-107 
with the sugar moiety (t1/2, 2.1 h) is slower compared to that for BW-CO-103 (t1/2, 1.2 h). However, 
in an aqueous solution, the CO release rate soared by 11 folds (t1/2, 0.18 h). This agrees with the 
higher reaction rate associated with the cycloaddition reaction in aqueous solution. 
 After the cyclization reaction, compounds BW-CO-107 led to the formation of blue 
fluorescent compounds BW-CP-107 which were characterized spectroscopically as shown in  
Table 1. The fluorescence quantum yield for these compounds are relatively close, and 
almost half that of the standard used, quinine sulfate with quantum yield of 0.58. These compounds 
can be used as fluorophores for in vitro and in vivo applications. 
Table 1: The chemical structures and CO release kinetics of CO prodrugs. 
 
compounds k[h-1][a] t1/2[h][b] λex[nm][c] λex[nm][d] ф[e] 
BW-CO-101: X = NMe, R1 = R2 = H, n = 1 22.4 ± 3.2/2.3 ± 0.2[f] 0.031 ± 0.004/0.3 ± 0.03[f] 371 450 0.21 
BW-CO-102: X = NMe, R1 = TBDPS, R2 = H, n = 1 22.6 ± 0.2 0.031 ± 0.0003 378 456 0.21 
BW-CO-103: X = N-iso-Pr, R1 = R2 = H, n = 2 0.57 ± 0.03 1.2 ± 0.1 373 456 0.18 
BW-CO-104: X = N-iso-Pr, R1 = Me, R2 = H, n = 2 0.11 ± 0.03 6.2 ± 0.2 372 464 0.17 
BW-CO-105: X = O, R1 = H, R2 = H, n = 1 - > one week[g] 367 454 0.14 
BW-CO-106: X = NH, R1 = R2 = H, n = 1 - > one week[g] 370 456 0.18 
BW-CO-101: X =  , R1 = R2 = H, n = 1 
 
 
 
 
 
0.33 ± 0.01/3.8 ± 0.12[f] 
 
 
 
 
 
2.1 ± 0.1/0.18 ± 0.005 
 
 
 
 
 
370 
 
 
 
 
 
458 
 
 
 
 
 
0.21 
[a] CO release rate was determined by monitoring the increase of fluorescence intensity in 
DMSO/PBS (pH 7.4) 5:1 at 378C. [b] Half-life for CO release. [c] The excitation wavelength of 
the cycloaddition products BW-CP-101–BW-CP-107. [d] The emission wavelength of the 
cycloaddition products BW-CP-101–BW-CP-107. [e] The quantum yield of the cycloaddition 
products BW-CP-101–BW-CP-107 in MeOH was determined using quinine sulfate as the 
standard. [f] The CO release rate in CH2Cl2 at room temperature. [g] The CO release rate was 
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determined in [D6 ]DMSO/D2O (10:1) at 37 8C. [h] The CO release rate was determined in 1% 
of DMSO in PBS (pH 7.4); TBDPS: tert-butyldiphenylsilyl. 
3.2 Conclusion 
In conclusion, we have taken advantage of the inverse electron-demanded Diels Alder 
reaction in designing a click and release strategy for a unimolecular system for bioorthogonal CO 
prodrugs. In this system, both the dienones and non-activated alkyne were conjugated together via 
various tethering linkers. These series of CO prodrugs were stable during synthesis and storage 
and yet, readily undergo intramolecular cycloaddition reaction to release CO under physiological 
condition. The CO release rate varies from minutes to days and can be fine-tuned by varying the 
size, nature (lactam/lactone), substituents on the tether, and the electronic properties of the alkyne. 
The cyclized products were characterized spectroscopically, and the result showed that they can 
be employed as fluorescent probes for cell imaging and diagnostic application. 
3.3 Experimental 
3.3.1 Spectroscopic properties for cyclized compounds 
 The fluorescence spectra for the cyclized compounds were taken in different solvents, 
including CH2Cl2 (DCM), CH3CN (ACN), and DMSO (Figure 16-22). 
 
Figure 16. The fluorescence spectra for BW-CP-101 (100 µM) in different solvents. 
Excitation wavelength is 371 nm. 
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Figure 17. The fluorescence spectra for BW-CP-102 (100 µM) in different solvents. 
Excitation wavelength is 370nm. 
 
 
Figure 18. The fluorescence spectra for BW-CP-103 (100 µM) in different solvents. 
Excitation wavelength is 373nm. 
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Figure 19, The fluorescence spectra of BW-CP-106 (100 μM) in different solvents. 
Excitation wavelength is 370 nm. 
 
 
Figure 20, The fluorescence spectra of BW-CP-107 (50 μM) in different solvents. 
Excitation wavelength is 370 nm. 
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Figure 21, The fluorescence spectra of BW-CP-108 (50 μM) in different solvents. 
Excitation wavelength is 372nm. 
 
 
Figure 22, The fluorescence spectra for BW-CP-109 (100 μM) in different solvents. 
Excitation wavelength is 370 nm. 
3.3.2 Quantum Yield Determination 
The quantum yields of compounds BW-CP-101 - 109 were determined by a comparative 
method using a well characterized quantum yield standard quinine sulfate (Φ = 0.54 in 0.05M of 
H2SO4). Briefly, a series of solutions of compounds and standard with different concentrations (4, 
8, 12, 16 and 20 μM) were prepared, and the UV absorbance at their excitation wavelength was 
taken. Then the fluorescence of the same solution were recorded. The integrated fluorescence were 
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plotted against the absorbance, and the quantum yield for the compounds was calculated according 
to the following equation:  
Φx = ΦST(Gradx/GradST)( ηx2/ηST2) 
Where the subscripts ST and x denote standard and compound respectively; Φ is the 
fluorescence quantum yield; Grad is the gradient from the plot of integrated fluorescence intensity 
against absorbance; and η is the refractive index of the solvent. Shown in Figures 23-30 are the 
obtained results.  
 
 
Figure 23. Plot of absorbance against integrated fluorescence intensity for the standard 
(excitation wavelength = 370 nM) 
 
 
Figure 24. Plot of absorbance against integrated fluorescence intensity for BW-CP-101 
(excitation wavelength = 370 nM), Φ = 0.21 
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Figure 25. Plot of absorbance against integrated fluorescence intensity for BW-CP-102 
(excitation wavelength = 378 nM), Φ = 0.21 
 
 
Figure 26. Plot of absorbance against integrated fluorescence intensity for BW-CP-103 
(excitation wavelength = 373nM), Φ = 0.18 
 
y = 307999x + 2302.1
R² = 0.9985
0
5000
10000
15000
20000
25000
30000
0 0.02 0.04 0.06 0.08 0.1
Compound BW-CP-102
In
tegrated
  Flu
o
re
scen
ce
Absorbance
y = 267289x + 1410.3
R² = 0.9986
0
5000
10000
15000
20000
0 0.01 0.02 0.03 0.04 0.05 0.06 0.07
Compound BW-CP-103
Absorbance
In
tegrated
  Flu
o
re
scen
ce
50 
 
Figure 27. Plot of absorbance against integrated fluorescence intensity for BW-CP-104 
(excitation wavelength = 372 nM), Φ = 0.17 
 
 
Figure 28. Plot of absorbance against integrated fluorescence intensity for BW-CP-105 
(excitation wavelength = 367 nM), Φ = 0.14 
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Figure 29. Plot of absorbance against integrated fluorescence intensity for BW-CO-106 
(excitation wavelength = 370 nM), Φ = 0.18 
 
 
Figure 30. Plot of absorbance against integrated fluorescence intensity for BW-CO-107 
(excitation wavelength = 370 nM), Φ = 0.20 
3.3.3 Studies of the CO Release Kinetics 
The fluorescence of the cyclized product BW-CO-101 - 104, and 107-109 greatly 
facilitates the studies of CO release kinetics. Briefly, the fluorescence intensity of the cyclized 
product were monitored at different time point. The fluorescence intensity was plotted against 
time, and the obtained curve was fitted using Sigmaplot to get the first order reaction rate constant. 
The half-life was calculated according to the equation: t1/2 = 0.689/k. 
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3.3.4 The CO release of BW-CO-101 in different solvent 
BW-CO-101 was dissolved in different solvent including CH2Cl2 (25 
oC), CH3CN (25 
oC), 
DMSO (25 oC), DMSO/PBS (10:1, 25 oC), DMSO/PBS (5:1, 25 oC), and DMSO/PBS (5:1, 37 oC) 
to give a final concentration of around 100 μM, and CO release was monitored by fluorescence 
intensity at 450 nm. Each experiment was repeated three times independently.  
 
Figure 31. The CO release rate in different solvent 
As shown in Fig. 31, the CO release rate (first order reaction rate) in DCM, ACN, DMSO, 
DMSO/PBS (10:1), DMSO/PBS (5:1), and DMSO/PBS (5:1, 37oC) were different and their 
individual rate constant was calculated to be 2.3±0.2, 3.6±0.4, 6.6±0.6, 7.7±0.6, 11.0±1.4 and 
22.4±3.2 h-1, respectively. The corresponding half-life for the CO release was 18, 11, 6, 5, 4, and 
2 min, respectively. The CO release rate increased along with the polarity of the solvent. 
3.3.5 The CO release rate of BW-CO-102-109 under physiological conditions 
By a similar method used for studying the kinetics of compound BW-CO-101, the CO 
release rate constants for BW-CO-102-104 and 107-109 were obtained (Figure 32-38). 
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Figure 32. The CO release kinetics for BW-CO-102 (100 μM), t1/2 = 1.8 min. 
 
 
Figure 33, The CO release kinetics for BW-CO-103 (100 μM), t1/2 = 1.2 h. 
 
 
Figure 34, The CO release kinetics for BW-CO-104 (50 μM), t1/2 = 6.3 h. 
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Figure 35, The CO release kinetics for compound BW-CO-107 (50 μM, DMSO/PBS = 
5:1) t1/2 = 0.55 h. 
 
 
Figure 36, The CO release kinetics for compound BW-CO-108 (50 μM, DMSO/PBS = 
5:1) t1/2 = 12 min. 
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Figure 37, The CO release kinetics for compound BW-CO-109 (50 μM, DMSO/PBS = 
5:1), t1/2 = 2.1 h. 
 
 
Figure 38, The CO release kinetics for compound BW-CO-109 (30 μM) in 1% of DMSO 
in PBS (7.4), t1/2 = 0.18 h. 
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APPENDIX 
1H and 13C Spectra of compounds in chapter 2 
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MS of compounds in chapter 2 
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